SUDA Enters Agreement To Develop Cannabinoid Spray
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- SUDA Receives R&D Tax Incentive Refund
- ZolpiMist Market Update
- SUDA Signs Agreement For SUD-001H For US Market
- Appendix 4C, Market Update and Top 20
- Request for Trading Halt
Later from Arovella Therapeutics
- ZLD to Invest in Development of Oral Spray Formulations
- SUDA Signs Agreement With Mitsubishi Tanabe
- Appendix 4C Amended
- ArTiMist Regulatory Update
- Product Development Market Update
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics